Provention Bio Inc., a young company advancing two phase II-ready assets from Janssen Research & Development LLC and a vaccine platform technology from Finland's Vactech Oy, has raised its first financing, $28.4 million, in a private placement of series A preferred stock that closed April 25. Provention will use proceeds of the offering to develop the assets through proof of concept.